{"id":"allob-implantation","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"ALLOB® contains allogeneic bone-forming cells that are implanted directly at the site of bone defects. These cells are designed to differentiate into mature osteoblasts and integrate into the bone matrix, promoting new bone formation and healing of skeletal defects.","oneSentence":"Allogeneic osteoblastic cells that differentiate into bone-forming cells to promote bone regeneration at the site of implantation."},"_scrapedAt":"2026-03-28T04:33:36.836Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123522,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Bone morphogenetic protein-2 (BMP-2)","brand":"INFUSE","company":"Medtronic","rationale":"Protein-based bone graft substitute for spinal fusion and fractures"},{"name":"Autologous bone graft","brand":null,"company":null,"rationale":"Standard of care for bone regeneration procedures"},{"name":"Synthetic bone graft substitutes","brand":null,"company":null,"rationale":"Alternative materials for bone void filling and regeneration"}],"description":"ALLOB® is an investigational cell-based therapy developed by Bone Therapeutics for bone regeneration. It consists of allogeneic osteoblastic cells derived from healthy donors, designed to promote bone formation in patients with bone defects or fractures requiring surgical intervention.","indications":{"approved":[{"status":"investigational","condition":"Delayed-union fractures","patientPopulation":"Adult patients requiring bone regeneration"},{"status":"investigational","condition":"Bone defects requiring surgical intervention","patientPopulation":"Adult patients"}]},"trialDetails":[{"nctId":"NCT02020590","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures","status":"COMPLETED","sponsor":"Bone Therapeutics S.A","startDate":"2014-02","conditions":"Long Bone Delayed-Union Fracture","enrollment":25},{"nctId":"NCT04432389","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture","status":"UNKNOWN","sponsor":"Bone Therapeutics S.A","startDate":"2021-01-08","conditions":"Tibial Fracture","enrollment":178},{"nctId":"NCT02205138","phase":"PHASE2","title":"Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion","status":"COMPLETED","sponsor":"Bone Therapeutics S.A","startDate":"2014-10","conditions":"Degenerative Disc Disease","enrollment":38},{"nctId":"NCT02328287","phase":"PHASE2","title":"Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion","status":"TERMINATED","sponsor":"Bone Therapeutics S.A","startDate":"2014-09","conditions":"Failed Lumbar Fusion","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ALLOB® implantation","genericName":"ALLOB® implantation","companyName":"Bone Therapeutics S.A","companyId":"bone-therapeutics-s-a","firstApprovalDate":"","aiSummary":"ALLOB implantation is being studied for its potential to treat various conditions, including Long Bone Delayed-Union Fracture, Failed Lumbar Fusion, Tibial Fracture, and Degenerative Disc Disease. The treatment involves the implantation of ALLOB, an allogeneic osteoblastic cell product, which is being investigated in clinical trials such as NCT02020590.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}